Clinical trials
Polycythemia Vera clinical trials
Below are recruiting polycythemia vera clinical trials, each written for real people, not researchers. We’re tracking 43 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07232290RecruitingPhase 2
Flonoltinib for people with polycythemia vera
This study tests a new pill, flonoltinib, for people with polycythemia vera whose blood counts are hard to control and who have not responded well to or couldn't tolerate current treatments. The goal is to see if the pill can lower the number of red blood cells and reduce symptoms, potentially reducing the need for frequent blood removal procedures.
TianjinAges 18 years+ - NCT07648030RecruitingPhase 2
Rusfertide for polycythemia vera in Japanese adults
This study tests a new medicine called rusfertide for polycythemia vera (PV)—a blood condition where your body makes too many red blood cells. The trial aims to see if rusfertide can help reduce the need for blood removal procedures (phlebotomy) that PV patients currently need to manage their condition.
Nagoya, Aichi-kenAges 18 years+ - NCT04116502RecruitingPhase 3
Ruxolitinib versus standard treatments for high-risk polycythemia vera
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
AberdeenAges 18 years+ - NCT06093672RecruitingPhase 3
Comparing givinostat vs hydroxyurea for polycythemia vera
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
Birmingham, AlabamaAges 18 years+ - NCT06752746RecruitingPhase 1
Testing 9MW3011 for polycythemia vera in resistant patients
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Zhengzhou, HenanAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT07429266RecruitingPhase 3
Study of sapablursen for phlebotomy-dependent polycythemia vera
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
Miami, FloridaAges 18 years+ - NCT07012109RecruitingPhase 1
A trial of BEBT-507 for people with polycythemia vera
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04644211RecruitingPhase 2
Ruxolitinib for symptom control in certain blood cancer types
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
Boston, MassachusettsAges 18 years+ - NCT06506084Recruiting
Study of ropeginterferon alfa-2b for polycythemia vera
This study looks at how well a drug called ropeginterferon alfa-2b works for people with polycythemia vera. It aims to understand the drug's effects and safety when used as a first or later treatment option.
Bergamo, LombardyAges 18–100 - NCT05882773Recruiting
Registry for adults with certain blood cancers
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
Hong KongAges 18 years+ - NCT06743035Recruiting
Study of ropeginterferon for polycythemia vera without enlarged spleen
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
Hanover, Lower SaxonyAges 18 years+ - NCT06351631RecruitingPhase 3
Long-term safety study of bomedemstat for blood cancers
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
Ann Arbor, MichiganAges 18 years+ - NCT07469891RecruitingPhase 1
Study of PRT12396 for JAK2-positive blood cancers
This trial tests an experimental drug, PRT12396, for people with certain blood cancers (polycythemia vera or myelofibrosis) that have a specific JAK2 mutation. It aims to see if the drug is safe and starts to work against the disease.
Denver, ColoradoAges 18 years+ - NCT06218628RecruitingPhase 1
Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06327100RecruitingPhase 1/Phase 2
Tasquinimod for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
Houston, TexasAges 18 years+ - NCT06343805RecruitingPhase 1
Study of AJ1-11095 for myelofibrosis after failed JAK2 inhibitor
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
Palo Alto, CaliforniaAges 18 years+ - NCT07357727RecruitingPhase 3
Study of Pelabresib and Ruxolitinib for Myelofibrosis
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
New Haven, ConnecticutAges 18 years+ - NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Gilbert, ArizonaAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT06361641Recruiting
Study of immune cells in blood cancers
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
Angers, Maine et LoireAges 18 years+ - NCT05714072RecruitingPhase 1
Ruxolitinib plus abemaciclib for myelofibrosis after ruxolitinib
This trial tests whether adding abemaciclib to ongoing ruxolitinib can better control myelofibrosis in people who are not getting enough benefit from ruxolitinib alone. It is designed to see safety and response in a specific group with intermediate-2 or high-risk disease and ongoing symptoms or enlarged spleen.
Basking Ridge, New JerseyAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT04655092RecruitingPhase 3
Extension study for people finishing prior P1101 treatment
This is an “extension” trial for people who already completed a 52-week P1101 study and agreed to continue. It tests whether continuing P1101 after the original study is safe and beneficial for certain patients.
Toon-shi, EhimeAges 20 years+
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Polycythemia Vera trials by city
Studies with a site in or near these metro areas.
Polycythemia Vera trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for polycythemia vera?
- Yes. Clin2 currently lists 43 recruiting polycythemia vera studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a polycythemia vera trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a polycythemia vera trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.